Page last updated: 2024-08-21

arsenic trioxide and Granulocytic Leukemia, Chronic

arsenic trioxide has been researched along with Granulocytic Leukemia, Chronic in 58 studies

Research

Studies (58)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.72)	18.2507
2000's	27 (46.55)	29.6817
2010's	28 (48.28)	24.3611
2020's	2 (3.45)	2.80

Authors

Authors	Studies
Abeltino, M; Armando, F; Bonati, A; Bonifacio, M; Cantoni, AM; Corradi, A; Ferrari, A; Gambacorti-Passerini, C; Jottini, S; Lombardi, G; Lunghi, P; Martinelli, G; Mazzera, L; Peli, A; Perris, R; Ricca, M; Ripamonti, A; Rossetti, E; Scupoli, MT; Visco, C	1
Antosik, P; Czajkowska, P; Durślewicz, J; Gagat, M; Grzanka, A; Grzanka, D; Hałas-Wiśniewska, M; Klimaszewska-Wiśniewska, A	1
Fan, L; Hu, A; Li, F; Liang, J; Liu, C; Mu, CF; Xiong, Y	1
Hu, X; Li, X; Liu, T; Peng, Y; Tan, W; Wei, X; Zhang, X; Zhao, Z	1
Hanamura, I; Hosokawa, Y; Hyodo, T; Kanasugi, J; Karnan, S; Konishi, H; Mizuno, S; Ota, A; Rahman, ML; Takami, A; Tsuzuki, S; Wahiduzzaman, M	1
Hejazi, NS; Hubbard, AE; Loguinov, A; Sobh, A; Tagmount, A; Vulpe, CD; Yazici, GN; Zeidan, RS; Zhang, L	1
Bazarbachi, A; El Eit, R; Itani, AR; Jabbour, M; Mahon, FX; Nasr, R; Nassar, F; Rasbieh, N; Santina, A; Zaatari, G	1
Du, Y; Fang, H; Xia, Y; Zhang, J	1
Ayoubi, HR; Bazarbachi, AA; Bitar, NM; De Thé, HB; El Eit, RM; Iskandarani, AN; Jabbour, MN; Mahfouz, RA; Mahon, FX; Nasr, RR; Saliba, JL; Zaatari, GS	1
Fei, J; Feng, M; Li, Y; Luo, X; Zhang, Y; Zhu, X	1
Altman, JK; Beauchamp, E; Eklund, EA; Goussetis, DJ; Kosciuczuk, EM; Platanias, LC; Wu, EJ	1
Wei, W; Wu, C; Wu, Y; Xu, W; Yan, H; Ye, C; Yu, Q	1
Lei, H; Ma, CM; Song, LL; Tu, YY; Wang, WW; Wei, W; Wen, DH; Wu, YL; Xia, L; Xu, HZ	1
Du, Y; Li, NN; Lyu, FF; Wang, W	1
He, XW; Yan, W; Yang, W	1
Fan, RF; Fang, ZG; Lin, DJ; Liu, XF; Lu, Y; Pan, GZ; Zhai, FX	1
Chuah, C; Melo, JV	1
Fang, H; Wang, K; Zhang, J	1
Kneifel, C; Lösler, S; Rojewski, MT; Schlief, S; Schrezenmeier, H; Thiel, E	1
Cortes, J; Giles, F	1
Dong, D; Fei, J; Gu, J; Hu, H; Huang, K; Li, Y; Lin, C; Yao, J; Zhu, X	1
Dong, D; Fei, J; Gu, J; Huang, K; Li, Y; Lin, C; Yao, J; Zhu, X	1
Altman, JK; Dolniak, B; Glaser, H; Goussetis, DJ; Kroczynska, B; McNeer, JL; Platanias, LC; Sassano, A	1
Essers, M; Trumpp, A; Wilson, A	1
Kashimura, M; Ohyashiki, K	1
Gui-Nan, L; Guo-Bao, W; Jie, L; Qi-Rong, G; Xiao-Qin, C; Yue, L	1
Hirao, A; Hoshii, T; Naka, K	1
Chen, R; Huang, S; Li, G; Liang, Y; Liu, L; Liu, Q; Wu, Y; Yin, D; Zhang, B	1
Bao, Y; Duan, Y; Kong, J; Liu, Z; Ma, X; Shan, B; Wang, Y; Wu, X	1
Fei, J; Li, Y; Luo, X; Zhu, X	1
Altman, JK; Bogyo, M; Gounaris, E; Goussetis, DJ; Platanias, LC; Sharma, B; Vakana, E; Wu, EJ	1
Gounaris, E; Goussetis, DJ; Platanias, LC	1
Auberger, P	1
Li, H; Wang, X; Wang, Z; Xu, Z; Yue, X; Zhang, X	1
Druker, BJ; Johnson, K; La Rosée, P; O'Dwyer, ME	1
Choi, HI; Kim, HJ; Kim, T; Lee, IS; Shim, MJ; Yang, SJ	1
Akiharu, W; Jing, HM; Ke, XY; Yoshiro, K; Yukihiro, S	1
Li, L; Zhang, R; Zhu, ZL	1
Corbin, AS; Deininger, MW; Druker, BJ; Johnson, K; La Rosée, P; Mauro, MM; Melo, JV; Moseson, EM; Stoffregen, EP; Willis, S	1
Bali, P; Bhalla, K; Fuino, L; Guo, F; Houghton, P; Nimmanapalli, R; O'Bryan, E; Wu, J	1
Alvarez, RH; Cortes, JE; Giles, F; Kantarjian, HM; O'Brien, SM; Talpaz, M	1
Chen, ZC; Li, WM; Liu, ZP; Wu, XF; You, Y; Zou, P	1
Arthur, JS; Kannan-Thulasiraman, P; Katsoulidis, E; Platanias, LC; Tallman, MS	1
Pu, Q	1
Davis, RJ; Giafis, N; Higgins, LS; Katsoulidis, E; Nebreda, AR; Platanias, LC; Sassano, A; Tallman, MS	1
Meng, L; Meng, R; Sui, XH; Yang, BF; Zhou, J	1
Aleskog, A; Barbany, G; Bengtsson, M; Björnberg, A; Höglund, M; Larsson, R; Lindhagen, E; Olsson-Strömberg, U; Simonsson, B	1
Altman, J; Giafis, N; Katsoulidis, E; Mears, H; Platanias, LC; Redig, AJ; Sassano, A; Smith, J; Tallman, MS; Yoon, P	1
Bertoglio, J; Bréard, J; Potin, S	1
Härtel, N; Hehlmann, R; Hochhaus, A; Konig, H; La Rosée, P; Lorentz, C; Melo, JV; Schatz, M; Schultheis, B	1
Chen, GQ; Wang, LS; Wu, YL; Yu, Y	1
Fu, YB; Li, CY; Li, L; Meng, FY; Song, LL; Sun, QX; Yi, ZS	1
Avigan, DE; Bernardi, R; Ikeda, Y; Ito, K; Matsuoka, S; Morotti, A; Pandolfi, PP; Rosenblatt, J; Saglio, G; Teruya-Feldstein, J	1
Kwong, YL; Todd, D	1
Bhalla, KN; Fang, G; Kim, CN; Perkins, C	1
Brüggenolte, N; Güller, S; Hoelzer, D; Orleth, A; Ottmann, OG; Puccetti, E; Ruthardt, M	1
O'Dwyer, M	1
Bhalla, KN; Druker, BJ; La Rosée, P; Nimmanapalli, R; O'Dwyer, ME	1

Reviews

8 review(s) available for arsenic trioxide and Granulocytic Leukemia, Chronic

Article	Year
Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. Hematology. American Society of Hematology. Education Program, 2008 Topics: Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Amplification; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles	2008
Transcriptome and proteome analyses of drug interactions with natural products. Current drug metabolism, 2008, Volume: 9, Issue:10 Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Drug Discovery; Drug Synergism; Gene Expression Profiling; Herb-Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Proteome; Pyrimidines; Tretinoin	2008
New agents in chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network : JNCCN, 2003, Volume: 1, Issue:4 Topics: Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Cytosine; Dioxolanes; Farnesyltranstransferase; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Vaccination	2003
Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer science, 2010, Volume: 101, Issue:7 Topics: Animals; Arsenic Trioxide; Arsenicals; beta Catenin; Bone Marrow; Cell Cycle; Cytarabine; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Oxides; Protein Kinase Inhibitors; Protein-Tyrosine Kinases	2010
Investigational strategies in chronic myelogenous leukemia. Hematology/oncology clinics of North America, 2004, Volume: 18, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Cancer Vaccines; DNA Methylation; Enzyme Inhibitors; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Research; Treatment Outcome	2004
Leukemia, an effective model for chemical biology and target therapy. Acta pharmacologica Sinica, 2007, Volume: 28, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin	2007
Multifaceted approach to the treatment of bcr-abl-positive leukemias. The oncologist, 2002, Volume: 7 Suppl 1 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Enzyme Inhibitors; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis; Treatment Outcome	2002
Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. Seminars in hematology, 2002, Volume: 39, Issue:2 Suppl 1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Enzyme Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2002

Trials

1 trial(s) available for arsenic trioxide and Granulocytic Leukemia, Chronic

Article	Year
Effects of arsenic trioxide administration styles on leukocytosis. Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2006, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Humans; Infusions, Intravenous; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides	2006

Article

Year

Effects of arsenic trioxide administration styles on leukocytosis.

Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2006, Volume: 21, Issue:2

Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Humans; Infusions, Intravenous; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides

2006

Other Studies

49 other study(ies) available for arsenic trioxide and Granulocytic Leukemia, Chronic

Article	Year
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia. Leukemia, 2023, Volume: 37, Issue:8 Topics: Animals; Apoptosis; Arsenic Trioxide; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Protein Kinase Inhibitors	2023
Cellular and molecular alterations induced by low‑dose fisetin in human chronic myeloid leukemia cells. International journal of oncology, 2019, Volume: 55, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Antagonism; Drug Screening Assays, Antitumor; Drug Synergism; Flavonoids; Flavonols; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive	2019
Dual oligopeptides modification mediates arsenic trioxide containing nanoparticles to eliminate primitive chronic myeloid leukemia cells inside bone marrow niches. International journal of pharmaceutics, 2020, Apr-15, Volume: 579 Topics: Acetates; Animals; Arsenic Trioxide; Bone Marrow; Cell Proliferation; Cells, Cultured; Drug Delivery Systems; Female; Human Umbilical Vein Endothelial Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Nanoparticles; Neoplastic Stem Cells; Oligopeptides; Organometallic Compounds; Polymers; Tumor Stem Cell Assay	2020
Smart Human-Serum-Albumin-As Angewandte Chemie (International ed. in English), 2017, 08-28, Volume: 56, Issue:36 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Folate Receptor 2; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Nanoparticles; Neoplasms, Experimental; Serum Albumin, Human; Structure-Activity Relationship	2017
Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo. Cancer letters, 2018, 10-01, Volume: 433 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Forkhead Box Protein O1; Forkhead Box Protein O3; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphorylation; STAT5 Transcription Factor; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays	2018
Functional Profiling Identifies Determinants of Arsenic Trioxide Cellular Toxicity. Toxicological sciences : an official journal of the Society of Toxicology, 2019, 05-01, Volume: 169, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Cell Survival; CRISPR-Cas Systems; Dose-Response Relationship, Drug; Gene Editing; Gene Expression Profiling; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Signal Transduction; Sodium Selenite; Time Factors; Transcriptome	2019
Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Cancer, 2019, 08-15, Volume: 125, Issue:16 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Autophagy; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hedgehog Proteins; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred BALB C; Mice, Transgenic; Protein Kinase Inhibitors	2019
Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide. Experimental biology and medicine (Maywood, N.J.), 2013, Aug-01, Volume: 238, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Time Factors; Treatment Outcome	2013
Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha. International journal of cancer, 2014, Feb-15, Volume: 134, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Bone Marrow Transplantation; Cell Transformation, Neoplastic; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Oxides; Piperazines; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Survival Rate; Tumor Cells, Cultured; Tumor Stem Cell Assay	2014
VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia. Hematology (Amsterdam, Netherlands), 2013, Volume: 18, Issue:6 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligodeoxyribonucleotides, Antisense; Oxides; Piperazines; Pyrimidines; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2013
Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors. Cancer biology & therapy, 2014, Volume: 15, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Drug Synergism; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Oxides; Resveratrol; Stilbenes	2014
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms. Molecular medicine reports, 2014, Volume: 10, Issue:3 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Poly(ADP-ribose) Polymerases; Pyrazines; Pyrimidines; Reactive Oxygen Species; RNA, Messenger	2014
Targeting catalase but not peroxiredoxins enhances arsenic trioxide-induced apoptosis in K562 cells. PloS one, 2014, Volume: 9, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cell Line, Tumor; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Peroxiredoxins; Reactive Oxygen Species	2014
[Effect of arsenic trioxide on differentiation induction of chronic myeloid leukemia k562 cells and its potential mechanism]. Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:1 Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Oxides; RNA, Messenger; Transcription Factors; Up-Regulation	2015
[Effect of As₂O₃on Hedgehog Pathway in Chronic Myeloid Leukemia Cells]. Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:4 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Down-Regulation; Hedgehog Proteins; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction	2015
RUNX3 plays an important role in As2O3‑induced apoptosis and allows cells to overcome MSC‑mediated drug resistance. Oncology reports, 2016, Volume: 36, Issue:4 Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Core Binding Factor Alpha 3 Subunit; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mesenchymal Stem Cells; Microscopy, Fluorescence; Middle Aged; Oxides; Polymerase Chain Reaction; Young Adult	2016
Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system. Annals of hematology, 2009, Volume: 88, Issue:11 Topics: Antimony; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Caspase Inhibitors; Caspases; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Glutathione; HL-60 Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, T-Cell; Membrane Potential, Mitochondrial; Neoplasm Proteins; Oxidation-Reduction; Oxides	2009
miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Proliferation; Flow Cytometry; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; MicroRNAs; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured	2011
Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer science, 2010, Volume: 101, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Cell Cycle; G1 Phase; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oligonucleotides; Oxides; RNA-Binding Proteins; Up-Regulation	2010
Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1. Molecular pharmacology, 2010, Volume: 77, Issue:5 Topics: Acetylcysteine; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dithiothreitol; Enzyme Activation; Genetic Variation; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; Oxides; Phosphorylation; Protein Kinases; Reactive Oxygen Species; RNA, Small Interfering; Tretinoin; U937 Cells	2010
Awakening dormant haematopoietic stem cells. Nature reviews. Immunology, 2010, Volume: 10, Issue:3 Topics: Animals; Arsenic Trioxide; Arsenicals; Bone Marrow; Cell Growth Processes; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Mice; Oxides; Stem Cell Niche	2010
Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia. Leukemia research, 2010, Volume: 34, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Prognosis; Pyrimidines; Translocation, Genetic	2010
Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line. Leukemia & lymphoma, 2010, Volume: 51, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Bone Marrow Cells; Cell Adhesion; Cell Survival; Cells, Cultured; Coculture Techniques; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Inhibitory Concentration 50; Integrin beta1; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Stromal Cells	2010
miR-153 sensitized the K562 cells to As2O3-induced apoptosis. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oxides; Real-Time Polymerase Chain Reaction	2012
AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib. Leukemia research, 2011, Volume: 35, Issue:10 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Blotting, Western; Cells, Cultured; Cytidine Deaminase; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Mutation; Oxides; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction	2011
Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells. Cellular signalling, 2012, Volume: 24, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; ral GTP-Binding Proteins; RNA Interference; RNA, Small Interfering	2012
Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood, 2012, Oct-25, Volume: 120, Issue:17 Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Autophagy-Related Protein 7; Cathepsin B; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysosomes; Oxides; Phosphorylation; Plasmids; Primary Cell Culture; Proteolysis; Sequestosome-1 Protein; Signal Transduction; Transfection; Ubiquitin-Activating Enzymes	2012
BCR-ABL1-induced leukemogenesis and autophagic targeting by arsenic trioxide. Autophagy, 2013, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Oxides; Translational Research, Biomedical	2013
BCR-ABL/p62/SQSTM1: a cannibal embrace. Blood, 2012, Oct-25, Volume: 120, Issue:17 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Signal Transduction	2012
Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution. Biological & pharmaceutical bulletin, 2013, Volume: 36, Issue:4 Topics: Acidithiobacillus; Antineoplastic Agents; Apoptosis; Aquaporins; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; RNA, Messenger; Solutions; Sulfides	2013
In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Experimental hematology, 2002, Volume: 30, Issue:7 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Biomarkers, Tumor; Caspase 3; Caspases; Cell Division; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Tumor Cells, Cultured; Tumor Stem Cell Assay	2002
Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase. Journal of biochemistry and molecular biology, 2002, Jul-31, Volume: 35, Issue:4 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Enzyme Activation; Enzyme Inhibitors; Humans; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microscopy, Electron; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Mitogen-Activated Protein Kinases; Oxides; p38 Mitogen-Activated Protein Kinases; Pyridines	2002
Effect of arsenic trioxide on different cell lines derived from chronic myeloid leukemia. Zhongguo shi yan xue ye xue za zhi, 2002, Volume: 10, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Division; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; In Situ Nick-End Labeling; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Tumor Cells, Cultured	2002
[Down-regulation of expression of vascular endothelial growth factor induced by arsenic trioxide in bone marrow cells of chronic myeloid leukemia]. Zhongguo shi yan xue ye xue za zhi, 2003, Volume: 11, Issue:3 Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cells, Cultured; Child; Culture Media, Conditioned; Down-Regulation; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphokines; Male; Middle Aged; Oxides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood, 2004, Jan-01, Volume: 103, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Benzamides; Cell Division; Cell Line, Tumor; Decitabine; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2004
Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer research, 2003, Nov-15, Volume: 63, Issue:22 Topics: 3-Phosphoinositide-Dependent Protein Kinases; 5' Untranslated Regions; Apoptosis; Arsenic Trioxide; Arsenicals; Down-Regulation; Eukaryotic Initiation Factor-4E; Fusion Proteins, bcr-abl; Genes, abl; HL-60 Cells; Humans; Jurkat Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Protein Biosynthesis; Protein Serine-Threonine Kinases; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger	2003
[Protein kinase C inhibitor Gö6976 sensitizes arsenic trioxide-induced cell apoptosis in chronic myeloid leukemic cells]. Zhongguo shi yan xue ye xue za zhi, 2005, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carbazoles; Cell Cycle; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Protein Kinase C; Time Factors	2005
Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide. The Journal of biological chemistry, 2006, Aug-11, Volume: 281, Issue:32 Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Enzyme Activation; Fibroblasts; Histones; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Knockout; Oxides; p38 Mitogen-Activated Protein Kinases; Ribosomal Protein S6 Kinases, 90-kDa; Stem Cells	2006
[Further improving the standard of treatment for chronic myeloid leukemia]. Zhonghua nei ke za zhi, 2006, Volume: 45, Issue:5 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cancer Vaccines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Tumor Necrosis Factor-alpha	2006
Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer research, 2006, Jul-01, Volume: 66, Issue:13 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Mice; Mice, Knockout; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation	2006
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis. Anti-cancer drugs, 2006, Volume: 17, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Cytarabine; Daunorubicin; Feasibility Studies; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; In Vitro Techniques; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Vincristine	2006
Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Molecular cancer therapeutics, 2006, Volume: 5, Issue:11 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Phosphorylation; Protein Kinases; Protein-Tyrosine Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured	2006
Involvement of a Rho-ROCK-JNK pathway in arsenic trioxide-induced apoptosis in chronic myelogenous leukemia cells. FEBS letters, 2007, Jan-09, Volume: 581, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 9; Humans; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Neoplasm Proteins; Oxides; Protein Serine-Threonine Kinases; rho GTP-Binding Proteins; rho-Associated Kinases	2007
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells. Haematologica, 2007, Volume: 92, Issue:6 Topics: Arsenic Trioxide; Arsenicals; Benzamides; Buthionine Sulfoximine; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Glutathione; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines	2007
[STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2007, Volume: 27, Issue:11 Topics: Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Oxides; Piperazines; Pyrazines; Pyrimidines; Tumor Cells, Cultured	2007
PML targeting eradicates quiescent leukaemia-initiating cells. Nature, 2008, Jun-19, Volume: 453, Issue:7198 Topics: Adult; Animals; Arsenic Trioxide; Arsenicals; Cell Line; Coculture Techniques; Female; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Recurrence; Regeneration; Transcription Factors; Tumor Suppressor Proteins	2008
Delicious poison: arsenic trioxide for the treatment of leukemia. Blood, 1997, May-01, Volume: 89, Issue:9 Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Differentiation; Fatal Outcome; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Oxides; Splenomegaly	1997
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood, 2000, Feb-01, Volume: 95, Issue:3 Topics: Acetylation; Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; bcl-2-Associated X Protein; bcl-X Protein; Caspases; Cytochrome c Group; Cytosol; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fas Ligand Protein; fas Receptor; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, bcl-2; Histones; HL-60 Cells; Humans; Immunophenotyping; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrophage-1 Antigen; Membrane Glycoproteins; Mitochondria; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oxides; Protein Biosynthesis; Protein Processing, Post-Translational; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2	2000
BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer research, 2000, Jul-01, Volume: 60, Issue:13 Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blast Crisis; Cells, Cultured; Colony-Forming Units Assay; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Jurkat Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Philadelphia Chromosome; Proto-Oncogene Proteins c-abl; Tumor Cells, Cultured; U937 Cells	2000